A phase II clinical trial to evaluate the efficacy of the antiviral vaccine GP120 depleted HIV 1 vaccine [RG 83894] in antiretroviral-naive patients with HIV infection.
Phase of Trial: Phase II
Latest Information Update: 30 Dec 2016
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary) ; Vaccines
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms Study215
- Sponsors Orchestra Therapeutics
- 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.
- 01 Dec 2005 New trial record.